GZ/SAR402671
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fabry Disease
Conditions
Fabry Disease
Trial Timeline
Jul 7, 2015 → Nov 20, 2018
NCT ID
NCT02489344About GZ/SAR402671
GZ/SAR402671 is a phase 2 stage product being developed by Sanofi for Fabry Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02489344. Target conditions include Fabry Disease.
What happened to similar drugs?
9 of 20 similar drugs in Fabry Disease were approved
Approved (9) Terminated (4) Active (10)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02489344 | Phase 2 | Completed |
| NCT02228460 | Phase 2 | Completed |
Competing Products
20 competing products in Fabry Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lucerastat | Idorsia | Phase 3 | 38 |
| Fabrazyme (agalsidase beta) | Sanofi | Phase 2 | 35 |
| Venglustat (GZ402671) + Placebo | Sanofi | Phase 3 | 44 |
| Fabrazyme (agalsidase beta) + Fabrazyme (agalsidase beta) | Sanofi | Phase 2 | 27 |
| agalsidase beta | Sanofi | Approved | 35 |
| Tropicamide | Sanofi | Pre-clinical | 26 |
| Fabrazyme (agalsidase beta) | Sanofi | Approved | 35 |
| agalsidase beta | Sanofi | Approved | 43 |
| AGALSIDASE BETA (GZ419828) + Acetaminophen + Diphenhydramine + Dexamethasone + Montelukast + Loratadine + Cetirizine + Fexofenadine | Sanofi | Approved | 43 |
| Gabapentin + placebo | Sanofi | Phase 2 | 27 |
| Agalsidase beta | Sanofi | Approved | 43 |
| GZ/SAR402671 | Sanofi | Phase 2 | 35 |
| agalsidase beta (GZ419828) + agalsidase alfa | Sanofi | Approved | 35 |
| Fabrazyme (agalsidase beta) | Sanofi | Phase 3 | 40 |
| Venglustat (GZ402671) + Agalsidase alfa + Agalsidase beta (GZ419828) + Migalastat | Sanofi | Phase 3 | 44 |
| Iohexol | Sanofi | Phase 1 | 21 |
| Fabrazyme (agalsidase beta) | Sanofi | Phase 2 | 35 |
| Agalsidase beta | Sanofi | Approved | 43 |
| Fabrazyme (agalsidase beta) + Placebo | Sanofi | Approved | 43 |
| Agalsidase beta + Agalsidase beta | Sanofi | Phase 3 | 40 |